XGX Pharma ApS — Credit Rating and Financial Key Figures
CVR number: 32289290
Frederiksgade 11, 1265 København K
msa@vitalpharmanordic.com
tel: 70276627
Income statement (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 15 225.62 | 14 515.29 | 2 917.68 | 8 100.82 | 16 033.79 |
| Employee benefit expenses | -4 004.49 | -5 008.32 | -4 419.96 | -5 200.47 | -7 262.73 |
| Total depreciation | - 354.75 | - 434.13 | - 787.67 | -1 424.09 | -2 234.34 |
| EBIT | 10 866.38 | 9 072.84 | -2 289.95 | 1 476.26 | 6 536.73 |
| Other financial income | 18.58 | 5.79 | 0.58 | 7.70 | |
| Other financial expenses | - 532.38 | - 407.80 | - 484.94 | - 786.35 | - 873.21 |
| Net income from associates (fin.) | -2 148.44 | 143.13 | 87.85 | -82.30 | -50.52 |
| Pre-tax profit | 8 204.14 | 8 931.62 | -2 681.26 | 623.69 | 5 673.08 |
| Income taxes | -2 199.79 | -1 683.12 | 838.70 | - 162.79 | -1 219.65 |
| Net earnings | 6 004.35 | 7 248.51 | -1 842.55 | 460.89 | 4 453.43 |
Assets (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Development expenditure | 6 674.57 | 11 329.47 | 14 835.84 | 16 329.09 | 17 499.10 |
| Intangible rights | 649.94 | 668.50 | |||
| Intangible assets total | 6 674.57 | 11 329.47 | 14 835.84 | 16 979.03 | 18 167.60 |
| Machinery and equipment | 89.71 | 527.16 | 365.02 | 170.63 | 22.74 |
| Tangible assets total | 89.71 | 527.16 | 365.02 | 170.63 | 22.74 |
| Holdings in group member companies | 0.00 | 143.13 | 230.98 | 148.69 | 105.50 |
| Investments total | 61.05 | 334.61 | 437.94 | 381.67 | 341.70 |
| Long term receivables total | |||||
| Finished products/goods | 1 633.59 | 2 395.16 | 3 044.19 | 2 679.14 | 3 266.20 |
| Inventories total | 1 633.59 | 2 395.16 | 3 044.19 | 2 679.14 | 3 266.20 |
| Current trade debtors | 1 784.68 | 2 589.39 | 3 968.11 | 2 932.76 | 13 053.82 |
| Current amounts owed by group member comp. | 250.00 | 164.70 | 288.25 | ||
| Current other receivables | 14 628.54 | 3 627.18 | 4 508.67 | 6 144.47 | 3 736.89 |
| Current deferred tax assets | 65.45 | 204.44 | 479.90 | 148.80 | 129.00 |
| Short term receivables total | 16 478.67 | 6 671.02 | 8 956.68 | 9 390.73 | 17 207.96 |
| Balance sheet total (assets) | 24 937.59 | 21 257.41 | 27 639.68 | 29 601.20 | 39 006.20 |
Equity and liabilities (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Share capital | 132.98 | 132.98 | 400.00 | 400.00 | 400.00 |
| Shares repurchased | 7 000.00 | 4 000.00 | |||
| Other reserves | 5 206.16 | 9 039.08 | 11 819.74 | 12 885.38 | 13 747.46 |
| Retained earnings | -5 423.13 | -3 251.70 | 3 421.55 | 513.36 | -3 887.83 |
| Profit of the financial year | 6 004.35 | 7 248.51 | -1 842.55 | 460.89 | 4 453.43 |
| Shareholders equity total | 12 920.36 | 13 168.87 | 13 798.74 | 14 259.63 | 18 713.06 |
| Provisions | 1 444.11 | 2 508.61 | 1 669.91 | 1 832.71 | 3 052.36 |
| Non-current loans from credit institutions | 1 856.81 | 1 947.94 | 7 648.62 | 5 873.36 | 3 952.76 |
| Non-current liabilities total | 1 856.81 | 1 947.94 | 7 648.62 | 5 873.36 | 3 952.76 |
| Current loans from credit institutions | 378.52 | 0.06 | 1 775.26 | 2 370.73 | |
| Advances received | 752.55 | ||||
| Current trade creditors | 2 343.63 | 3 309.29 | 4 541.01 | ||
| Current owed to participating | 1.93 | ||||
| Current owed to group member | 55.81 | ||||
| Short-term deferred tax liabilities | 2 663.60 | 611.60 | |||
| Other non-interest bearing current liabilities | 5 674.18 | 3 020.33 | 1 370.42 | 2 550.96 | 6 374.35 |
| Current liabilities total | 8 716.31 | 3 631.99 | 4 522.41 | 7 635.51 | 13 288.02 |
| Balance sheet total (liabilities) | 24 937.59 | 21 257.41 | 27 639.68 | 29 601.20 | 39 006.20 |
Try the full version of our system for free
- Professional credit risk reports
- Create your own estimates for any company
- Valuation analysis
- All 400,000+ Danish companies
- See instructions
... and more!
No registration needed.